
Early data from the single-center evaluation of Zoom RDL ran in the Journal of Neurointerventional Surgery (JNIS). Imperative Care designed Zoom RDL as the first radial access platform developed specifically for treating ischemic stroke.
The Campbell, California-based company said it offers an alternative option to femoral access in treating stroke patients. It can help to enable the best possible outcome based on an individual patient’s anatomy. The system features an extended hydrophilic coating, optimized dilator and a long distal flexible segment.
Imperative Care said it designed Zoom RDL to provide .088″ intracranial access. According to the company, this demonstrated the ability to lead to faster and better reperfusion in stroke procedures.
“We are pleased to see early evidence support the use of Zoom RDL in helping physicians successfully achieve radial access in patients who might not be candidates for femoral access,” said Ariel Sutton, GM of Imperative Care’s stroke business. “Our patient-first portfolio includes two options for intracranial access, Zoom 88 for femoral access and Zoom RDL for radial access, empowering clinicians to choose the best option for their patients based on their anatomy. We look forward to future results that underscore the value of the Zoom Stroke Solution in helping physicians take more control over their stroke thrombectomies for quicker, more efficient procedures.”
About the Imperative Care analysis for Zoom RDL
Data came from 29 patients in the independent, retrospective, single-center evaluation of Zoom RDL. These patients underwent neurointerventional procedures between October 2022 and January 2023.
Results indicated that the system offers technical feasibility and effectiveness for complex neurointerventional procedures with low complication rates. Dr. Tareq Kass Hout, Dr. Rami Morsi, Dr. Harsh Desai, Dr. Sonam Thind and more conducted the evaluation. It took place at the University of Chicago Medical Center.
The study evaluated Zoom RDL in a range of neurointerventional procedures. Stroke thrombectomies comprised 31% (9/29) of those procedures. Imperative Care set a primary outcome measure as successful access to the target vessel without needing to convert to a different guide catheter or transfemoral access.
Results demonstrated success in this outcome in 90% (26/29) of the cases. Success occurred in 100% (9/9) of stroke patients. Most cases resulted in TICI 2c reperfusion or better within one pass (67%, 6/9). Imperative Care reported no access site or product-related complications. However, the company disclosed two procedure-related complications. Those included one intracerebral hemorrhage and one intraprocedural thrombus formation.
“Adoption of transradial access for neurointerventional procedures is at an early phase with the need for additional data supporting its use. One reason behind limited adoption of transradial access, especially in mechanical thrombectomy, has been the lack of a purpose-built access catheter,” said Kass-Hout. “Zoom RDL fulfills this need as the first radial access catheter platform built specifically for stroke, with an inner diameter that accommodates large bore aspiration catheters and the provided ability to navigate the intracranial ICA from the radial artery.”